History of drug use in allogeneic hematopoietic cell transplant recipients (Sep, 10.1038/s41409-020-01058-z, 2020)

Abou-Ismail Mouhamed Yazan; Ravi Gayathri; Fu Pingfu; Cao Shufen; Vuyyala Sowjanya; Caimi Paolo; Kolk Merle; Ferrari Nicole; Boughan Kirsten; Cooper Brenda; Gallogly Molly; Otegbeye Folashade; Tomlinson Benjamin; de Lima Marcos; Metheny Leland

首页> 外文期刊>Bone marrow transplantation >History of drug use in allogeneic hematopoietic cell transplant recipients (Sep, 10.1038/s41409-020-01058-z, 2020)

【24h】

History of drug use in allogeneic hematopoietic cell transplant recipients (Sep, 10.1038/s41409-020-01058-z, 2020)

机译：异种造血细胞移植受体中药物用途（SEP，10.1038 / S41409-020-01058-Z，2020）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

机译：已发布对本文的修订，并可通过纸张顶部的链接访问。

著录项

来源
《Bone marrow transplantation》 |2021年第3期|共1页
作者
Abou-Ismail Mouhamed Yazan; Ravi Gayathri; Fu Pingfu; Cao Shufen; Vuyyala Sowjanya; Caimi Paolo; Kolk Merle; Ferrari Nicole; Boughan Kirsten; Cooper Brenda; Gallogly Molly; Otegbeye Folashade; Tomlinson Benjamin; de Lima Marcos; Metheny Leland;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. History of drug use in allogeneic hematopoietic cell transplant recipients [J] . Yazan Abou-Ismail Mouhamed, Ravi Gayathri, Fu Pingfu, Bone marrow transplantation . 2021,第3期

机译：异种造血细胞移植受者的药物用途
2. Erratum: Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: A retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (Bone Marrow Transplantation (2013) 48 (1513-1518) DOI: 10.1038/bmt.2013.140)) [J] . KanamoriH., MizutaS., KakoS., Bone marrow transplantation . 2013,第12期

机译：勘误：缓解期50岁或50岁以上B细胞ALL缓解患者的同种异体干细胞移植：日本造血细胞移植学会成人ALL工作组的回顾性研究（骨髓移植（2013）48 1513-1518 DOI：10.1038 / bmt.2013.140））
3. Transfusion policy: when to stop the use of extremely rare blood for an allogeneic hematopoietic progenitor cell transplant recipient with a history of red cell alloimmunization. [J] . Senzel L, Boulad F, Wuest D, Transfusion: The Journal of the American Association of Blood Banks . 2007,第5期

机译：输血政策：何时停止使用具有罕见红细胞同种免疫史的同种异体造血祖细胞移植受者使用极罕见的血液。
4. THE EFFECT OF INHIBITORY KILLER-CELL IG-LIKE RECEPTOR (IKIR) MATCHING IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) [C] . David Senitzer, Joel Y. Sun, Arisa Oki, Clinical Histocompatibility Workshop. . 2009

机译：同种异体造血细胞移植（HCT）中抑制杀伤细胞IG样受体（IKIR）匹配的影响
5. Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians. [D] . Tay, Jason. 2009

机译：接受同种异体造血干细胞移植的患者的供体选择：加拿大造血干细胞移植医生的优先事项评估。
6. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors transplant conditions and myelotoxic drugs [O] . Hirohisa Nakamae, Barry Storer, Brenda M. Sandmaier, 2011

机译：同种异体造血细胞移植第28天后的Cytopenias：受体/供体因素移植条件和骨髓毒性药物的影响
7. Correction: History of drug use in allogeneic hematopoietic cell transplant recipients [O] . Mouhamed Yazan Abou-Ismail, Gayathri Ravi, Pingfu Fu, 2020

机译：矫正：同种异体造血细胞移植受者的药物用史
8. Guidance for Industry and FDA Staff: Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System. [R] . 2014

机译：工业和FDa工作人员指南：针对影响造血系统的疾病患者的造血和免疫重建的最小操作，无关异体胎盘/脐带血的研究性新药申请。

History of drug use in allogeneic hematopoietic cell transplant recipients (Sep, 10.1038/s41409-020-01058-z, 2020)

摘要

著录项

相似文献

相关主题

期刊订阅